Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03815643 · ClinicalTrials.gov registry record · Phase 3
Avelumab Program Rollover Study
A Phase 3 study of Solid Tumors, sponsored by EMD Serono Research & Development Institute.
- Active
- Registry status
- Phase 3
- Development phase
- 205
- Enrollment target
- 20
- Study locations
NCT03815643: Active Phase 3 study of Solid Tumors, sponsored by EMD Serono Research & Development Institute.
NCT03815643 is a Phase 3 study of Solid Tumors that is active but no longer recruiting, run by EMD Serono Research & Development Institute. The registered enrollment target is 205 participants, below the 283-participant average among 125 other Solid Tumors trials with a reported enrollment target (28% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03815643, a Phase 3 study of Solid Tumors, is active but no longer recruiting, sponsored by EMD Serono Research & Development Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 205 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to monitor the safety and tolerability of avelumab in participants with solid tumors who continue treatment with avelumab under the same treatment regimen as in the parent avelumab study.
Conditions Studied
Interventions
- DRUG Avelumab
Study Locations (20)
Ohio
- University of Cincinnati - PARENT - Cincinnati
- Oncology Hematology Care - Cincinnati
- Oncology/Hematology Care Clinical Trials, LLC - Cincinnati
- OSU - James Comprehensive Cancer Center - Columbus
California
- University of California Davis Health System - Comprehensive Cancer Center - Sacramento
- Providence Medical Foundation - Santa Rosa
- St Joseph Heritage Healthcare - Santa Rosa
South Carolina
- Medical University of South Carolina (MUSC) - Charleston
- Greenville Hospital System University Medical Center (ITOR) - Upstate Affiliate Organization - Greenville
Arizona
- HonorHealth Research Institute - Scottsdale
Arkansas
- Highlands Oncology Group - Fayetteville
Connecticut
- Norwalk Hospital - The Whittingham Cancer Center - Norwalk
Florida
- Hematology - Oncology Associates of the Treasure Coast - Hematology-Oncology Associates of Treasure Coast - Port Saint Lucie
Georgia
- Northwest Georgia Oncology Centers - Marietta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 205 participants |
| Start Date | 2019-03-22 |
| Est. Completion | 2027-02-19 |
| Phase | Phase 3 |
What the registry record for NCT03815643 still lists
NCT03815643 is an interventional study that assigns participants to a tested intervention. The registered 205 participants enrollment target is mid-sized for trials with a published cap, below the 283-participant average among 125 other Solid Tumors trials with a reported enrollment target (28% lower).
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which Avelumab is the first listed.
NCT03815643 names 20 study sites across 14 states, led by Ohio, California, South Carolina.
Frequently Asked Questions
What is clinical trial NCT03815643 about?
NCT03815643 is a clinical study titled "Avelumab Program Rollover Study". The main purpose of this study is to monitor the safety and tolerability of avelumab in participants with solid tumors who continue treatment with avelumab under the same treatment regimen as in the parent avelumab study.
What is the current status of trial NCT03815643?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 205 participants. The study started on 2019-03-22. Estimated completion is 2027-02-19.
What conditions does trial NCT03815643 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT03815643?
The interventions under investigation include: Avelumab (DRUG).
Who is sponsoring clinical trial NCT03815643?
This trial is sponsored by EMD Serono Research & Development Institute, which has 81 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03815643 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03815643's enrollment target sits among peer trials
205 28th of 125 higher than 98 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
RECRUITING · Phase 3
-
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
ACTIVE NOT RECRUITING · Phase 3
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials
RECRUITING · Phase 4
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03457493 · 205 participants · Phase 1
The University of Alabama At Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy
- NCT05134857 · 205 participants · Phase 2
The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study
- NCT05181891 · 205 participants · Phase 2
Pharmaceutically-Enhanced Reinforcement for Reduced Alcohol and Smoking
- NCT05283811 · 205 participants · NA
Understanding Prefrontal and Medial Temporal Neuronal Responses to Algorithmic Cognitive Variables in Epilepsy Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI